253 related articles for article (PubMed ID: 38604295)
1. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
[TBL] [Abstract][Full Text] [Related]
2. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
4. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
5. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
6. Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis V; Papatheodoridis GV
Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
[TBL] [Abstract][Full Text] [Related]
7. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
; ; ;
Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
[TBL] [Abstract][Full Text] [Related]
8. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
Meroni M; Longo M; Dongiovanni P
Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
[No Abstract] [Full Text] [Related]
10. MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.
Phoolchund AGS; Khakoo SI
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254750
[TBL] [Abstract][Full Text] [Related]
11. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
; ; ;
J Hepatol; 2024 Jun; ():. PubMed ID: 38851997
[TBL] [Abstract][Full Text] [Related]
12. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
; ;
Obes Facts; 2024 Jun; ():1-70. PubMed ID: 38852583
[TBL] [Abstract][Full Text] [Related]
13. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
[TBL] [Abstract][Full Text] [Related]
14. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC.
Lee MH; Chen YT; Huang YH; Lu SN; Yang TH; Huang JF; Yin SC; Yeh ML; Huang CF; Dai CY; Chuang WL; Yu ML; Yang HI; Chen HY; Chen CJ
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1275-1285.e2. PubMed ID: 38365094
[TBL] [Abstract][Full Text] [Related]
15. MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.
Leyh C; Coombes JD; Schmidt HH; Canbay A; Manka PP; Best J
J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672997
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and the risk of hepatocellular carcinoma: a nationwide cohort study.
Jeong S; Oh YH; Ahn JC; Choi S; Park SJ; Kim HJ; Lee G; Son JS; Jang H; Lee DH; Sha M; Chen L; Kim W; Park SM
Clin Mol Hepatol; 2024 May; ():. PubMed ID: 38711390
[TBL] [Abstract][Full Text] [Related]
17. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
19. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.
Ma Y; Wang J; Xiao W; Fan X
Front Med (Lausanne); 2024; 11():1410668. PubMed ID: 38895182
[TBL] [Abstract][Full Text] [Related]
20. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]